The goal of this \[type of study:clinical trial\] is to \[learn about\] in \[Clinical IVB stage oral squamous cell carcinoma patients\]. The main question it aims to answer are:
• \[Observing the effectiveness and safety of the combination of Adebrelimab and TP regimen in neoadjuvant therapy for clinical IVB stage oral squamous cell carcinoma patients\] Participants will \[Received treatment with Adebrelimab combined with TP regimen, followed by surgery after 2 cycles of neoadjuvant therapy. After surgery, radiotherapy and chemotherapy combined with immunotherapy were chosen based on the patient\'s condition, with a total follow-up of two years.\].
Oral squamous cell carcinoma patients diagnosed by histology or cytology;
Has not received any treatment for oral squamous cell carcinoma in the past;
According to the AJCC TNM staging system, stage clinical IVB;
ECOG score: 0-1 points;
There are uncontrollable pleural effusion, pericardial effusion, or abdominal effusion that require repeated drainage;
Have a history of allergies to any components of adelbizumab in the past;
Received any other investigational medication within 4 weeks prior to the first use of the investigational medication, or had a half-life of no more than 5 weeks from the last investigational medication;
Simultaneously enroll in another clinical study, unless it is an observational (non intervention) clinical study or an intervention clinical study follow-up;
Single group
Adebrelimab
DrugAdebrelimab：20mg/kg, ivdrip, D1，Q3W
Effective mitigation rate（EMR）
Pathological complete remission（PCR）+Major pathological relief（MPR）
DFS
Disease free survival
R0 resection rate
:R0 is the ratio of no residue under the microscope after resection
ORR
Objective response rate
mOS
Median overall survival
Click on the lead sponsor to view all of their trials.
